A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
Observational Study
Prostatic Neoplasms, Castration-Resistant
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 115
- Sex
- Male
- Study type
- Observational
- Participants needed
- 17,111 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
* Male sex at index, where index is the date of initial mCRPC diagnosis.
* Age 18 years at index.
Exclusion criteria:
• None
Contacts
Novartis Pharmaceuticals
CONTACT